Unfractionated Heparin Safety in COVID-19: Incidence and Risks of Bleeding Complications in Japan

Overview

Journal J Atheroscler Thromb

Date 2024 Feb 14

PMID 38355124

Authors

Lubna Sato

Noriko Iwamoto

Yuko Kakumoto

Shinya Tsuzuki

Tomiteru Togano

Masahiro Ishikane

Nobumasa Okumura

Gen Yamada

Makoto Inada

Tetsuya Suzuki

Masayuki Hojo

Jin Takasaki

Ryo Sasaki

Akio Kimura

Katsuji Teruya

Tatsuya Okamoto

Kayoko Hayakawa

Hisao Hara

Ken Iseki

Norio Ohmagari

Affiliations

Soon will be listed here.

Abstract

Aim: Several studies have shown the efficacy and safety of low-molecular-weight heparin use in coronavirus disease 2019 (COVID-19), but that of unfractionated heparin (UFH) has not been investigated. We investigated the prevalence of bleeding complications during UFH administration, its impact on mortality, and the risk factors of bleeding outcomes associated with UFH.

Methods: This retrospective cohort study was conducted at a single-center tertiary care hospital, including hospitalized patients with COVID-19. The primary outcomes were measured as the prevalence of bleeding complications during hospitalization, and the secondary outcomes were thromboembolic events and 60-day mortality rates. Logistic regression analysis and propensity score matching were used to assess risk factors for bleeding complications and their impact on mortality.

Results: Among 1035 included patients, 516 patients were treated with UFH. Twelve (2.3%) patients in the UFH group experienced major bleeding. The prevalence of major bleeding in patients treated with therapeutic-dose UFH was 9.2%. Logistic regression analysis showed that age ≥ 60 years (adjusted odds ratio [aOR], 3.89; 95% confidence interval [CI], 1.01-15.0; P＜.05) and COVID-19 severity (aOR, 35.9; 95% CI, 4.57-282; P＜.05) were associated with major bleeding complications. After propensity score matching, 11 major and 11 non-major bleeding cases (including minor bleeding) were matched. The 60-day cumulative mortality rate between the two groups did not differ significantly (P=.13, log-rank test).

Conclusions: The incidence of major bleeding in COVID-19 patients using therapeutic-dose UFH was relatively high. Critical COVID-19 and older age were risk factors for bleeding complications.

References

Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes A, Di Nisio M . Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020; 196:67-74. PMC: 7420982. DOI: 10.1016/j.thromres.2020.08.020. View

Horiuchi H, Morishita E, Urano T, Yokoyama K . COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020. J Atheroscler Thromb. 2021; 28(4):406-416. PMC: 8147567. DOI: 10.5551/jat.RPT001. View

Sholzberg M, Tang G, Rahhal H, AlHamzah M, Kreuziger L, Ainle F . Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021; 375:n2400. PMC: 8515466. DOI: 10.1136/bmj.n2400. View

Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger J . Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020; 324(8):799-801. PMC: 7372509. DOI: 10.1001/jama.2020.13372. View

OBrien E, Simon D, Thomas L, Hylek E, Gersh B, Ansell J . The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015; 36(46):3258-64. PMC: 4670965. DOI: 10.1093/eurheartj/ehv476. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Cheng S, Morrow D, Sloan S, Antman E, Sabatine M . Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation. 2009; 119(9):1195-202. DOI: 10.1161/CIRCULATIONAHA.108.814996. View

Feinbloom D, Freed J, Carbo A, Jung Y, Adra M, Herzig S . Incidence and risk factors for PTT prolongation in patients receiving low-dose unfractionated heparin thromboprophylaxis. J Thromb Thrombolysis. 2020; 52(1):331-337. DOI: 10.1007/s11239-020-02294-2. View

Sadeghipour P, Talasaz A, Rashidi F, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M . Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized.... JAMA. 2021; 325(16):1620-1630. PMC: 7974835. DOI: 10.1001/jama.2021.4152. View

10.

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

11.

Di Minno A, Ambrosino P, Calcaterra I, Di Minno M . COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin Thromb Hemost. 2020; 46(7):763-771. PMC: 7645842. DOI: 10.1055/s-0040-1715456. View

12.

Lemos A, Espirito Santo D, Salvetti M, Gilio R, Agra L, Pazin-Filho A . Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020; 196:359-366. PMC: 7503069. DOI: 10.1016/j.thromres.2020.09.026. View

13.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

14.

Campbell N, Hull R, Brant R, Hogan D, Pineo G, Raskob G . Aging and heparin-related bleeding. Arch Intern Med. 1996; 156(8):857-60. View

15.

Iba T, Levy J, Levi M, Connors J, Thachil J . Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020; 48(9):1358-1364. PMC: 7255402. DOI: 10.1097/CCM.0000000000004458. View

16.

Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F . Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383(2):120-128. PMC: 7412750. DOI: 10.1056/NEJMoa2015432. View

17.

Alikhan R, Bedenis R, Cohen A . Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev. 2014; (5):CD003747. PMC: 6491079. DOI: 10.1002/14651858.CD003747.pub4. View

18.

Vedovati M, Mancuso A, Pierpaoli L, Paliani U, Conti S, Ascani A . Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. Int J Cardiol. 2019; 301:167-172. DOI: 10.1016/j.ijcard.2019.11.105. View

19.

Shimada Y, Nakra N, Fox J, Kanei Y . Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol. 2010; 105(5):629-32. DOI: 10.1016/j.amjcard.2009.10.043. View

20.

Katsoularis I, Fonseca-Rodriguez O, Farrington P, Jerndal H, Lundevaller E, Sund M . Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022; 377:e069590. PMC: 8984137. DOI: 10.1136/bmj-2021-069590. View